Provided by Tiger Trade Technology Pte. Ltd.

ADC Therapeutics SA

1.04
+0.07497.76%
Post-market: 1.03-0.0082-0.79%19:30 EDT
Volume:3.93M
Turnover:3.85M
Market Cap:132.13M
PE:-1.57
High:1.05
Open:0.9755
Low:0.9600
Close:0.9651
52wk High:4.98
52wk Low:0.7796
Shares:127.04M
Float Shares:88.56M
Volume Ratio:2.07
T/O Rate:4.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6636
EPS(LYR):-1.1224
ROE:-705.53%
ROA:-19.57%
PB:-0.58
PE(LYR):-0.93

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

ADC Therapeutics grants options for 49,400 shares to new employees under inducement plan

Reuters
·
May 01

ADC Therapeutics to host first-quarter results conference call and webcast

Reuters
·
Apr 27

ADC Therapeutics announces annual general meeting of shareholders

Reuters
·
Apr 11

Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
Apr 09

Redmile Group reports ADC Therapeutics disposal worth $10.1 million

Reuters
·
Apr 03

ADC Therapeutics grants 17,000-share option award under employee inducement plan

Reuters
·
Apr 02

ADC Therapeutics Sa : H.c. Wainwright Raises Target Price to $8 From $7

THOMSON REUTERS
·
Mar 23

U.S. RESEARCH ROUNDUP- ArriVent Biopharma, Aveanna Healthcare Holdings, EQT

Reuters
·
Mar 23

RBC Capital Sticks to Their Buy Rating for ADC Therapeutics (ADCT)

TIPRANKS
·
Mar 12

ADC Therapeutics files to sell 9.83M common shares for holders

TIPRANKS
·
Mar 11

ADC Therapeutics Sa - Selling Shareholders May Offer up to 9,834,776 Common Shares From Time to Time - SEC Filing

THOMSON REUTERS
·
Mar 11

ADC Therapeutics SA reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 10

ADC Therapeutics FY 2025 license revenues and royalties jumped 401% to USD 7.81 million

Reuters
·
Mar 10

Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend

Reuters
·
Mar 10

BRIEF-ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million

Reuters
·
Mar 10

ADC Therapeutics Q4 Operating Expenses USD -40.977 Million

THOMSON REUTERS
·
Mar 10

Press Release: ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Dow Jones
·
Mar 10